MAP2K7 and cardiofaciocutaneous syndrome: For example, in the Sos1E846K and KrasV14I mouse models of NS (Chen et al., 2010; Hernandez-Porras et al., 2014) and the BrafQ241R mouse model of CFC (Inoue et al., 2014), MEK inhibitors given prenatally effectively prevented the manifestations of the modeled RASopathy.